In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Novation's Orthopedics Suppliers, The Internet as Mediator

Executive Summary

For a variety of reasons, product companies have responded to the B2B supply chain phenomenon with reserve, wary of high transaction fees and little real benefit. B2B companies, in turn, have teamed up with leading hospital groups to overcome such resistance. But such a strategy only works where suppliers place a high value on GPO contracting. Where group contracting isn't well established, the approach works less well because there's no pull-through for the Internet program. But one group, Novation Inc., is in the early stages of an Internet program that would begin with one of the most challenging of group contracting markets: orthopedic suppliers.

You may also be interested in...



The Value of E-Commerce

For much of the past year, the promise of Internet-enabled e-commerce to deliver savings seemed just that: a promise. But a new study from Novation and Arthur Anderson goes a long way to finally putting some figures on the value and potential cost savings of a web-based supply chain.

More GMP Warnings, Import Alerts For OTC Firms As US FDA Capped List Of Uninspected Facilities

Most of the foreign OTC drug firms targeted in latest warnings FDA published, including the GUM oral care brand manufacturer, were placed on import alert due to GMP violations. Each was inspected by FDA during June, July or May 2019, when the agency was wrapping up an initiative to inspect all previously uninspected drug manufacturers.

AbbVie/Allergan Merger Edges Closer To FTC Clearance

AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.

Topics

UsernamePublicRestriction

Register

IV001511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel